Lyons, France

Pierre Garrone

USPTO Granted Patents = 11 

 

 

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 75(Granted Patents)


Location History:

  • Lyon, FR (2018)
  • Lyons, FR (1999 - 2024)

Company Filing History:


Years Active: 1999-2024

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Pierre Garrone: Innovator in Monoclonal Antibodies

Introduction

Pierre Garrone is a prominent inventor based in Lyons, France, known for his significant contributions to the field of biotechnology. With a total of 11 patents to his name, Garrone has focused on developing innovative solutions for medical diagnostics and treatments.

Latest Patents

Among his latest patents are groundbreaking inventions related to antibodies against Clostridium difficile toxins. These monoclonal antibodies are designed to bind to toxin A or toxin B, providing methods for detecting or treating infections and associated diseases. Additionally, he has developed humanized, mouse, or chimeric anti-CD47 monoclonal antibodies. These antibodies are engineered to bind to human glycosylated and deglycosylated CD47, disrupting the human CD47-SIRPα interaction. This innovation has potential applications in various therapeutic, preventive, or diagnostic methods. The patents also include isolated antibodies, derivatives, fragments, and pharmaceutical formulations, along with the amino acid and nucleotide sequences of the antibodies.

Career Highlights

Garrone has worked with notable companies in the biotechnology sector, including Schering Corporation and Forty Seven, Inc. His work has significantly advanced the understanding and application of monoclonal antibodies in medical science.

Collaborations

Some of his notable coworkers include Nicola Beltraminelli and Elizabeth Bates, who have collaborated with him on various projects in the field of antibody research.

Conclusion

Pierre Garrone's innovative work in monoclonal antibodies has made a substantial impact on medical diagnostics and treatment options. His patents reflect a commitment to advancing biotechnology for better health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…